Clinical trials: Influenza, completed
Influenza
A Clinical Trial With Influenza A/H1N1 Vaccines
A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (12-17 years) and children (3-11 years) to…
- Trial name
- NCT00956111
- Testing
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose, split-virion, adjuvanted H1N1 vaccine of 15 μg per dose, split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
- Where
- China
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza Like Illness
Seasonal Influenza Vaccine Effectiveness Study in Kenya
Influenza is an important cause of acute respiratory infections (ARI) worldwide. Seasonal influenza causes an estimated 250,000-500,000 deaths and 3-5 million severe illnesses each year (WHO, 2009), and pandemic 2009 H1N1…
- Conditions
- Influenza, Influenza Like Illness, Severe Acute Respiratory Illness
- Trial name
- NCT01432340
- Testing
- Seasonal influenza vaccine
- Where
- 2 sites in Kenya
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Gideon Emukule
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01138397
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 2 sites in Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Seasonal Influenza
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
- Trial name
- NCT01209780
- Testing
- TIV, TIVf, Comparator TIV
- Where
- 13 sites in Colombia, Mexico and 2 more
- Volunteers
- 3,116 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Common Cold, Influenza
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.
The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old…
- Trial name
- ACCORD (NCT02644018)
- Testing
- Imidazolyl ethanamide pentandioic acid
- Where
- 13 sites in Russia
- Volunteers
- 190 people
- Sponsor
- Valenta Pharm JSC
Influenza Vaccine, Immunocompromised Patients
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
This study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals.
- Trial name
- FluVacc (NCT06738082)
- Testing
- Influenza vaccine
- Where
- Switzerland
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pertussis/Whooping Cough, Influenza Viral Infections
Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
Pertussis is a bacterial respiratory infection caused by Bordetella pertussis. Highly contagious, it is potentially serious and even fatal in infants under 6 months of age.
- Trial name
- COVAGRIP (NCT05234229)
- Testing
- Survey
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Central Hospital, Nancy, France
Influenza
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, antigen and adjuvant dose-ranging Clinical study is evaluating different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04782323
- Testing
- aQII-1, aQII-3 Investigational, aQII-6 Investigational
- Where
- 30 sites in Australia, New Zealand and 2 more
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Text Messaging Reminders for Influenza Vaccine in Primary Care
Influenza morbidity and mortality cause a substantial financial burden to the NHS and to the UK as a whole. Influenza vaccine is safe and effective but is required annually because the circulating strain of virus changes each…
- Trial name
- TXT4FLUJAB (NCT01892631)
- Testing
- Text message influenza vaccination reminder, Standard care
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Healthy
A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers
This trial is to investigate the clinically recommended dosage for ASP7373 based on the comparison of the immunogenicity and safety among the three doses of ASP7373 in healthy adults.
- Trial name
- NCT01450579
- Testing
- ASP7373
- Where
- Japan
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should…
- Trial name
- NCT02544880
- Testing
- Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Donald T. Weed, MD, FACS
Influenza
Flu Shot Pre-visit Questionnaire
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of a pre-visit questionnaire that asks patients to indicate their preferences for a flu shot.
- Trial name
- NCT05508698
- Testing
- Precommitment Nudge, Salience
- Where
- United States
- Volunteers
- 230,962 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Influenza
Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate
The purpose of this phase IIb study is to demonstrate the consistency of three lots of an adjuvanted influenza vaccine candidate and to evaluate the safety of this vaccine compared to Fluarix™ administered intramuscularly in…
- Trial name
- NCT00321763
- Testing
- Candidate Influenza Vaccine GSK1247446A - 3 different formulations, Fluarix TM
- Where
- 46 sites in Estonia, France and 5 more
- Volunteers
- 3,124 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00479921
- Testing
- Trivalent influenza subunit vaccine
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza, Healthy
Genetic and Environmental Factors in the Response to Influenza Vaccination
The purpose of the study is to investigate and compare the immune responses to influenza vaccination in monozygotic (identical) and dizygotic (fraternal) twins to determine the roles of genetics and environment in the response to…
- Trial name
- SLVP028 (NCT03088904)
- Testing
- FluMist® Quadrivalent, Fluzone® Quadrivalent vaccine
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy, Gastrointestinal Dysfunction
Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues
The objective of the current study is to evaluate the effect of whole cell fermentate on gut health, including GI system function, such as supporting consistency and regularity of bowel habits, as well as changes in microbiota.
- Conditions
- Healthy, Gastrointestinal Dysfunction, Cold Symptom, Flu Symptom
- Trial name
- NCT04735809
- Testing
- Whole Cell Algae Fermentate
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Influenza Caused by the 2009 H1N1 Influenza Virus
Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11
A cohort of 3000 adults is followed to evaluate the effectiveness of the monovalent 2009 H1N1 vaccines used 2009-2010 and seasonal influenza vaccines used 2010-2011 in preventing the first laboratory-confirmed 2009 H1N1 influenza…
- Trial name
- NCT01206114
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 2,351 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.